Protein Sciences calls on Connecticut to buy its flu vaccine

Protein Sciences is calling on its home state to kickstart its entry into the flu vaccine sector by purchasing its shot. The Connecticut-based biotech won approval for its flu vaccine last year but it faces competition from GlaxoSmithKline ($GSK), Sanofi ($SNY) and the other established giants of the market. Protein Sciences' vaccine differs from these rivals because it is made using an insect cell-based production process. Article

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.